BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Merck Is Spending Like It Has a Problem. The Filed Numbers Say It Does.

Moe Alsumidaie by Moe Alsumidaie
November 11, 2026
in Research Notes
0
120
SHARES
2k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of the last decade, Merck ran a tidy business: one blockbuster drug, Keytruda, growing fast enough to carry everything else. Then 2026 arrived, and the company spent more than $15 billion in a single year on acquisitions and licensing deals, a sum larger than what the whole business earns in net income. That is not the behavior of a company riding high. It is the behavior of a company racing a clock.

The heart of it

The math, meaning what the filed numbers actually show, is a profitable business with a healthy net margin and growing revenue. The mood, meaning what the market pays today, is calm: a price-to-earnings multiple sitting right at Merck’s own decade median. But the price-to-sales multiple sits at the 96th percentile of its own history, which means the market is paying a near-record premium for each dollar of revenue at the exact moment that revenue’s most important source, Keytruda, faces a patent expiration in December 2028. Those two readings cannot both be right, and the gap between them is the story.

The clock on the shelf

Keytruda is the world’s best-selling oncology drug, with 2025 sales of $31.7 billion, more than half of Merck’s total revenue. Its primary U.S. compound patent expires in December 2028, per Patenta’s patent analysis. Related patents may push protection into late 2029, but the window is closing. Meanwhile, Januvia and Janumet, two older diabetes drugs that once padded the revenue line, lost U.S. market exclusivity in mid-2026. The company’s second-largest revenue stream is already eroding. What replaces Keytruda when biosimilars arrive is the question every dollar Merck spent this year is trying to answer.

The patent cliff is not a distant abstraction. It is a scheduled event, roughly two years out, that could remove the engine from the car, a structural fact the filed timeline makes concrete.

BullScope TerminalMRK was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Three bets, one year, $15 billion

Merck’s answer to that clock came in three installments. In January 2026, it completed the acquisition of Cidara Therapeutics, adding antiviral candidates to the pipeline. In March, it acquired Terns Pharmaceuticals, picking up an oral drug candidate for chronic myeloid leukemia. In September, it signed a licensing deal with SciBrunch Therapeutics for a preclinical KRAS inhibitor, a target that has frustrated oncology researchers for decades. Together, the 10-Q for the quarter ended September 30, 2026, records $15.1 billion in R&D charges from these three moves alone.

That $15.1 billion is not a capital investment that sits on the balance sheet and slowly depreciates. Under accounting rules, most of it flows directly through the income statement as an expense, which is why FY2023’s net margin collapsed to near zero after a similar acquisition wave, even as the underlying business was healthy. The same distortion is baked into 2026’s numbers. The business did not suddenly get worse. The accounting caught the spending.

Whether those bets pay off is genuinely unknown. Preclinical KRAS inhibitors have a long history of promising early data and disappointing late-stage results. The data cannot yet confirm that Cidara’s antiviral candidates will clear the FDA’s bar. What the filing does confirm is the size of the wager.

What is actually working

Two pipeline stories in the filing carry real, filed evidence behind them. The first is Keytruda’s own evolution. Merck is shifting the drug from an intravenous infusion, which requires a clinic visit, to a subcutaneous injection, meaning a shot under the skin that takes minutes. The new formulation, called Keytruda Qlex, grew from a small share of the Keytruda family in the second quarter of 2026 to $830 million in Q3 2026 sales. A faster, more convenient delivery method is harder for a biosimilar to replicate immediately, which gives Merck a modest runway beyond the compound patent date.

The second is sac-TMT in endometrial cancer. The FDA accepted a Priority Review application with a decision date of June 15, 2027, after trial data showed a 32% reduction in the risk of death. Separately, Merck’s collaboration with Moderna on a personalized melanoma vaccine, intismeran, showed a 42% cut in recurrence or death risk, with a regulatory filing targeted for 2026. These are not preclinical hopes. They are late-stage results with filed evidence behind them.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: MRK and 500+ other names, on the same official data.See the evidence engine →

The near-term pipeline carries genuine wins in the filed data. The open analytical question is whether they are large enough, and arrive fast enough, to offset the revenue hole Keytruda’s patent expiration would leave.

Reading the numbers

  • $15.1 billion in 2026 R&D charges (from the Q3 2026 10-Q). What it is: the accounting cost of three acquisitions and one licensing deal, expensed immediately. What it means here: it will suppress reported earnings for 2026 the same way a $1.4 billion charge suppressed FY2023’s margin to near zero, even though the underlying business kept generating cash. Everyday version: a household earning $100,000 a year that spends $30,000 on a single home repair looks broke on paper that year, but the house is still standing.
  • 28.1% net margin in FY2025 (from the FY2025 10-K). What it is: for every dollar of sales, Merck kept 28 cents after all costs. What it means here: the core business is genuinely profitable, which is what funds the $15 billion spending spree. Everyday version: a restaurant that clears 28 cents on every dollar of food sold can afford to renovate the kitchen without borrowing.
  • P/S at the 96th percentile of its own decade (BullScope Valuation Database, methodology at bullscope.ai/methodology/valuation-database; calculated from monthly closing price and trailing-twelve-month revenue, 2015–2025). What it is: the price-to-sales ratio, meaning the market’s price tag per dollar of revenue, sits higher than 96 of the last 100 comparable readings in Merck’s own history. What it means here: the market is paying a near-record premium for revenue that is about to face its biggest structural threat. Everyday version: paying a near-record price for a lease on a building whose anchor tenant has announced they are leaving in two years.

For the standing yardsticks on Merck & Co: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Merck & Co.

Sources

  • Merck 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • Merck 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Merck 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
  • Merck acquisitions, Tracxn
  • Merck/SciBrunch licensing deal, MarketScreener
  • Keytruda patent timeline, Patenta
  • Drug patent cliff 2026 to 2028, Patenta
  • FDA traditional approval for pembrolizumab in TMB-H solid tumors
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read MRK’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arvinas: the first PROTAC approved, and almost nothing left to show for it

by Moe Alsumidaie
November 13, 2026
0

Five years ago, Arvinas collected $650 million in a single wire transfer from Pfizer, the largest upfront payment any biotech had received for a drug that had not...

Read moreDetails

Jushi Holdings: $215 Million in Debt, $31 Million in Cash, and a Bet on Virginia

by Moe Alsumidaie
November 12, 2026
0

Jushi went public in December 2019 with a simple pitch: buy dispensary licenses in states before adult-use legalization arrived, then ride the wave. For a few years the...

Read moreDetails

Iovance: Revenue Is Real, the Losses Are Real, and the Pipeline Just Got More Complicated

by Moe Alsumidaie
November 11, 2026
0

For most of its life, Iovance Biotherapeutics was a research project wearing a company's clothes. It spent years and hundreds of millions of dollars teaching the immune system...

Read moreDetails

Ligand Pharmaceuticals: Royalties Are Surging. The Stock Price Assumes They Never Stop.

by Moe Alsumidaie
November 6, 2026
0

Ligand spent most of the last decade shedding things. It spun off its antibody discovery unit in November 2022, sold assets, and narrowed toward a single idea: own...

Read moreDetails

Harrow: Revenue Doubles, Equity Nearly Vanishes, and the Stock Is Down by Half

by Moe Alsumidaie
November 11, 2026
0

The quick read Harrow's filed numbers show revenue growing at a pace most pharmaceutical companies never see, more than fivefold in five years. The 10-Q filed for the...

Read moreDetails
Next Post

Iovance: Revenue Is Real, the Losses Are Real, and the Pipeline Just Got More Complicated

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Hill or Cliff? The One Exchange That Defines Merck Right Now

August 5, 2026

Evidence Sheet: Boeing (BA)

October 28, 2026

Evidence Sheet: Gilead Sciences (GILD)

November 2, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.